Glen Eagle Advisors’s Chemours CC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.9K | Hold |
720
| – | – | ﹤0.01% | 598 |
|
|
2025
Q4 | $8.49K | Sell |
720
-13
| -2% | -$167 | ﹤0.01% | 712 |
|
|
2025
Q3 | $11.6K | Buy |
733
+13
| +2% | +$189 | ﹤0.01% | 664 |
|
|
2025
Q2 | $8.24K | Hold |
720
| – | – | ﹤0.01% | 675 |
|
|
2025
Q1 | $9.74K | Hold |
720
| – | – | ﹤0.01% | 640 |
|
|
2024
Q4 | $12.2K | Hold |
720
| – | – | ﹤0.01% | 622 |
|
|
2024
Q3 | $14.6K | Hold |
720
| – | – | ﹤0.01% | 594 |
|
|
2024
Q2 | $16.3K | Buy |
720
+707
| +5,438% | +$18.5K | ﹤0.01% | 563 |
|
|
2024
Q1 | $341 | Hold |
13
| – | – | ﹤0.01% | 1042 |
|
|
2023
Q4 | $410 | Hold |
13
| – | – | ﹤0.01% | 977 |
|
|
2023
Q3 | $365 | Hold |
13
| – | – | ﹤0.01% | 980 |
|
|
2023
Q2 | $480 | Buy |
+13
| New | +$397 | ﹤0.01% | 1004 |
|
|
2022
Q3 | – | Sell |
-13
| Closed | -$416 | – | 1098 |
|
|
2022
Q2 | $416 | Buy |
+13
| New | +$478 | ﹤0.01% | 952 |
|
|
2022
Q1 | – | Sell |
-100
| Closed | -$3.36K | – | 948 |
|
|
2021
Q4 | $3.36K | Hold |
100
| – | – | ﹤0.01% | 752 |
|
|
2021
Q3 | $2.91K | Hold |
100
| – | – | ﹤0.01% | 880 |
|
|
2021
Q2 | $3.48K | Hold |
100
| – | – | ﹤0.01% | 854 |
|
|
2021
Q1 | $2.79K | Hold |
100
| – | – | ﹤0.01% | 848 |
|
|
2020
Q4 | $2.48K | Hold |
100
| – | – | ﹤0.01% | 830 |
|
|
2020
Q3 | $2.09K | Hold |
100
| – | – | ﹤0.01% | 797 |
|
|
2020
Q2 | $1.53K | Hold |
100
| – | – | ﹤0.01% | 777 |
|
|
2020
Q1 | $887 | Hold |
100
| – | – | ﹤0.01% | 763 |
|
|
2019
Q4 | $1.81K | Hold |
100
| – | – | ﹤0.01% | 786 |
|
|
2019
Q3 | $1.49K | Hold |
100
| – | – | ﹤0.01% | 733 |
|
|
2019
Q2 | $2.4K | Hold |
100
| – | – | ﹤0.01% | 684 |
|
|
2019
Q1 | $3.72K | Hold |
100
| – | – | ﹤0.01% | 607 |
|
|
2018
Q4 | $2.82K | Hold |
100
| – | – | ﹤0.01% | 606 |
|
|
2018
Q3 | $3.94K | Hold |
100
| – | – | ﹤0.01% | 586 |
|
|
2018
Q2 | $4.44K | Hold |
100
| – | – | ﹤0.01% | 556 |
|
|
2018
Q1 | $4.87K | Hold |
100
| – | – | ﹤0.01% | 532 |
|
|
2017
Q4 | $5.01K | Hold |
100
| – | – | ﹤0.01% | 513 |
|
|
2017
Q3 | $5.06K | Hold |
100
| – | – | ﹤0.01% | 520 |
|
|
2017
Q2 | $3.79K | Hold |
100
| – | – | ﹤0.01% | 501 |
|
|
2017
Q1 | $3.85K | Hold |
100
| – | – | ﹤0.01% | 478 |
|
|
2016
Q4 | $2.21K | Buy |
+100
| New | +$2.05K | ﹤0.01% | 492 |
|
Other funds holding CC
VPM
VCM
WHCM
Glen Eagle Advisors's CC Position: Q1 2026 in Review
Glen Eagle Advisors held its Chemours (CC) position steady in Q1 2026 at 720 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #598.
Glen Eagle Advisors first reported a position in CC in Q4 2016 and has held it in 34 quarters since. The position peaked at $16.3K in Q2 2024. 448 funds tracked by Wall St. Rank hold CC as of Q1 2026.
- Glen Eagle Advisors held 720 shares of Chemours worth $15.9K as of Q1 2026.
- Glen Eagle Advisors left its Chemours share count unchanged in Q1 2026.
- Chemours made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #598 holding.
- Glen Eagle Advisors first reported a position in Chemours in Q4 2016 and has held it in 34 quarters since.
- Glen Eagle Advisors's Chemours position peaked at $16.3K in Q2 2024.
- 448 funds tracked by Wall St. Rank held Chemours as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.